Close

Eleven Biotherapeutics (EBIO) Announces Effectiveness of Exclusive IL-6 Tech Licensing Agreement with Roche

Go back to Eleven Biotherapeutics (EBIO) Announces Effectiveness of Exclusive IL-6 Tech Licensing Agreement with Roche

Eleven Biotherapeutics Completes Exclusive Licensing Deal for IL-6 Antagonist Antibody Technology, Including EBI-031

August 16, 2016 7:30 AM EDT

Eleven entitled to $30 million payment

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced the effectiveness of the exclusive licensing deal with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (Roche). Eleven has granted Roche an exclusive, worldwide license to develop and commercialize EBI-031 and all other IL-6 antagonist antibody technology owned by Eleven. EBI-031 is a humanized monoclonal antibody that potently binds interleukin-6 (IL-6) and inhibits all known forms of IL-6 cytokine... More